Achieve Life SciencesACHV
Market Cap: $143M
About: Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.
Employees: 22
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
2,205% more call options, than puts
Call options by funds: $2.67M | Put options by funds: $116K
167% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 9
75% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 8
37% more funds holding
Funds holding: 41 [Q1] → 56 (+15) [Q2]
26% more capital invested
Capital invested by funds: $64.9M [Q1] → $81.5M (+$16.6M) [Q2]
7.94% more ownership
Funds ownership: 48.06% [Q1] → 56.0% (+7.94%) [Q2]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q1] → 1 (-1) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Oppenheimer Francois Brisebois 60% 1-year accuracy 18 / 30 met price target | 164%upside $11 | Outperform Reiterated | 15 Aug 2024 |
Financial journalist opinion
Based on 3 articles about ACHV published over the past 30 days